The study conducted by Syed et al. addressed the problem of immunohistochemistry supported by Gertsenshteyn et al. by evaluating 30 BT474 tumour-bearing mice that were treated with trastuzumab (monoclonal antibody against HER2; treated group) or with saline (control group) and imaged with 18F-MISO radiotracer [43]. This evidence concerns the gene ERBB2 and neoplasm.